Ask for a reprint
email :
* Give your email
2021
ACL
|
I.Da Silva, T.R.Johnson, J.C.Mixdorf, E.Aluicio-Sarduy, T.E.Barnhart, R.J.Nickles, J.W.Engle, P.A.Ellison, 'A High Separation Factor for 165Er from Ho for Targeted Radionuclide Therapy', Molecules 26 7513 (2021) doi:10.3390/molecules26247513
Radionuclides emitting Auger electrons (AEs) with low (0.02 ¬¬– 50 keV) energy, short (0.0007 ¬– 40 µm) range, and high (1 ¬– 10 keV/µm) linear energy transfer may have an important role in the targeted radionuclide therapy of metastatic and disseminated disease. Erbium-165 is a pure AE-emitting radionuclide that is chemically matched to clinical therapeutic radionuclide 177Lu, making it a useful tool for fundamental studies on the biological effects of AEs. This work develops new biomedical cyclotron irradiation and radiochemical isolation methods to produce 165Er suitable for targeted radionuclide therapeutic studies and characterizes a new such agent targeting prostate specific membrane antigen.
|
|
|